Cargando…
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
BACKGROUND: The Mucin-family protein, MUC1, impacts on carcinogenesis and tumor invasion. We evaluated the impact of MUC1 expression on outcome in a cohort of 158 patients with resected pancreatic ductal adenocarcinomas (PDAC) in the CONKO-001 study (adjuvant gemcitabine [gem] vs. observation [obs])...
Autores principales: | Striefler, Jana Käthe, Riess, Hanno, Lohneis, Philipp, Bischoff, Sven, Kurreck, Annika, Modest, Dominik Paul, Bahra, Marcus, Oettle, Helmut, Sinn, Marianne, Bläker, Henrik, Denkert, Carsten, Stintzing, Sebastian, Sinn, Bruno Valentin, Pelzer, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354141/ https://www.ncbi.nlm.nih.gov/pubmed/34386419 http://dx.doi.org/10.3389/fonc.2021.670396 |
Ejemplares similares
-
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
por: Sinn, M, et al.
Publicado: (2014) -
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018) -
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation
por: Striefler, Jana K., et al.
Publicado: (2022) -
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial
por: Pelzer, Uwe, et al.
Publicado: (2014) -
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial
por: Hoyer, K., et al.
Publicado: (2021)